论文部分内容阅读
本文采用随机、双盲、安慰剂对照试验评价雷尼替丁维持疗法预防复发性十二指肠球部溃疡的效果。方法 140例已治愈的十二指肠球部溃疡病人,治愈前均经内窥镜或X线确诊。研究前1周内内窥镜证实上消化道无活动性溃疡。研究前停用除抗酸剂以外的一切抗溃疡药至少3天。所有病人随机双盲口服雷尼替丁150mg或安慰剂每晚1次作为维持治疗,时间共2年。治疗12和24个月后或提示出现溃疡复发的持续性症状时分别行内窥镜检。若在研究结束前溃疡复发则停用维持治疗,给予标签公开的雷尼替丁(150mg每日2次)治疗4或8周,8周后若内窥镜证实溃
This randomized, double-blind, placebo-controlled trial evaluated the efficacy of ranitidine maintenance therapy in the prevention of recurrent duodenal ulcer. Methods 140 cases of duodenal ulcer patients have been cured, were cured before endoscopic or X-ray confirmed. Endoscopy confirms no upper gastrointestinal ulcer in the first week of the study. All anti-ulcer drugs except antacids were discontinued for at least 3 days prior to the study. All patients randomized double-blind oral ranitidine 150mg or placebo once a night as maintenance treatment, a total of 2 years. Endoscopy was performed separately after 12 and 24 months of treatment or when persistent signs of ulcer recurrence were indicated. If the ulcer recurrence was discontinued prior to the end of the study, ranitidine given (150 mg twice daily) was treated for 4 or 8 weeks, and after 8 weeks if endoscopy was confirmed